Your company is already operating in Germany and you would now like to export worldwide?

Pipette adding blue fluid test tube close up Pipette adding blue fluid test tube close up | © Stockphoto/Chet Chaimangkhalayon

Medical Biotechnology

Where Science, Innovation and Quality Meet

Germany’s biopharmaceuticals sector increased turnover by 14 percent last year, with the country’s biotech companies as important actors in the fight against Covid-19.

Germany is the world’s leading medical biotech nation behind the US. The industry’s strength comes from the presence of long-established and start-up companies alike. Industry, government, and the research sector are pulling in one direction to build on the thriving sector’s already strong market foundations. With the largest amount of biotech companies in Europe, world-class research infrastructure, and internationally renowned scientists, Germany has firmly established itself as an international medical biotechnology hub.

New Video: Germany's Medical Biotechnology Industry

Germany is one of the world’s leading biotechnology location. Most of the over 650 biotechnology companies are active in the medical sector.

Biopharmaceuticals Market Grows as Germany Leads in Fighting Covid-19

Germany’s biopharmaceuticals sector increased turnover by 14 percent last year, with the country’s biotech companies as important actors in the fight against Covid-19. 

Biopharmaceuticals turnover up to more than EUR 14 billion 

Germany’s biopharmaceuticals turnover (pharmacy and hospital market) grew to EUR 14.6 billion in 2020 – equivalent to a 14 percent year-on-year increase – according to the new Biotech Report compiled by the Boston Consulting Group for vfa bio. The report, the only one of its kind recording all medical biotechnology activity in Germany, records growth in nearly all fields of medical application and sees the sector increases its share of the total pharmaceuticals market to more than 30 percent.

Biopharmaceuticals to combat infection increase by 30 percent

The number of all biopharmaceuticals in clinical development increased by 2.7 percent, with 84 percent of the products in phase three being new biologics and the rest being biosimilars. Biopharmaceutical pipeline agents developed to combat infections increased by 30 percent in number in 2020, with one third of all agents being used specifically to counter the coronavirus. Twenty-seven new biopharmaceutical drugs (including biosimilars) were approved in 2020 – the second highest number recorded in Germany to date. 

German companies a leading force in the battle against Covid-19

German biotech companies have established themselves as international leaders in mRNA technologies, having secured a number of important firsts in the battle against the coronavirus including the first coronavirus test developed worldwide and the first Covid-19 vaccination approved by the European Medicines Agency. The number of companies grew by more than four percent in 2020, with the number of employees in the biopharmaceutical sector also up by more than five percent. 

Recombinant antibody therapies double in five year

The number of recombinant antibody therapies – for diseases not previously or insufficiently treatable – have also significantly increased in number. By the end of 2020, some 82 molecules of this class of active substances had been approved for use in Germany – twice as many as was the case just five years ago. Antibodies account for 32 percent of all approved biopharmaceuticals and, as such, represent the most important group. Innovations in recombinant DNA technology are allowing new antibody formats to be realized in the form of antibody derivatives that improve functionality, have a longer half-life and allow the binding of more than one antigen. 

Latest Publication

Fact Sheet: Biotechnology Clusters in Germany Fact Sheet: Biotechnology Clusters in Germany | © GTAI

Fact Sheet: Biotechnology Clusters in Germany

Germany features one of the best environments for biotechnology companies worldwide. Along the entire value chain Germany's biotechnology landscape is known for its outstanding capabilities, resources, and infrastructure.

Innovation Infrastructure

Science and industry need to work together closely in order for innovations to be commercialized successfully. German bioclusters are proving to be important new technology impulse givers in this respect.

Germany’s Bioregions

The BioRegions are regional initiatives for the advancement of modern biotechnology in Germany. Over the past three decades, these biotechnology clusters have developed to become Europe’s leading R&D hubs. Each region facilitates collaboration between universities, R&D institutes and private sector companies. Around 30 BioRegions are active members of AK Bioregio, whose goal is to advance the German biotechnology sector by coordinating and promoting local activities. AK BioRegio advances the exchange between regional initiatives and relays its expertise to political decision makers.

Investors benefit from easy access to networks and funding for research projects. The BioRegions also include technology parks tailored to the specific needs of biotechnology companies. Commonly known as BioParks, these centers offer an ideal infrastructure - including lab space and clean rooms - as well as a range of services for both start-up and well established companies.

Growth drivers: Biopharmaceuticals Market

Big pharmaceutical and smaller biotechnology companies alike are focusing on drug discovery and development of medicines produced by biotechnological processes.

Small molecules are moving to the background in medicine development as the result of a major paradigm shift to biopharmaceuticals. This is reflected by the increasing sales of biopharmaceutical products worldwide.

According to a report by Boston Consulting Group and the Association of Research-Based Pharmaceutical Companies (vfa), sales of biopharmaceuticals in Germany increased to EUR 10.2 billion in 2017 (growth of 10.3 percent compared to 2016). Growth was seen in nearly all fields of application, particularly in drugs treating immunological (e.g. rheumatic) diseases and cancer.

The number of biopharmaceuticals in clinical development increased from 604 in 2014 to 639 in 2017, reflecting continued high investment in the biopharmaceutical pipeline.

In 2017, a record-breaking 51% of all new drug approvals were biopharmaceuticals. By the end of 2017, a total of 274 biopharmaceutical drugs were approved for the German market – more than ever before. Divided into pharmacological classes, vaccines and monoclonal antibodies are leading in numbers with 23% each, followed by insulin with 14%.

Number of New Drug Approvals
Number of New Drug Approvals | © vfa/BCG: Medizinische Biotechnologie in Deutschland 2020
Biopharmaceuticals Value Growth Rate in Percent
Biopharmaceuticals Value Growth Rate in Percent | © BCG – Medizinische Biotechnologie in Deutschland 2020


Growth drivers: IVD & Molecular Diagnostics

In-vitro diagnostics (IVDs) are a crucial part of modern medicine: laboratory based tests performed on biological samples provide information that is key for the prevention, treatment and management of diseases. Today, around two third of all clinical diagnoses are made thanks to IVD´s. With more than EUR 2 bn in annual revenue, Germany represents the largest IVD market in Europe and second worldwide behind the USA.

Diagnostic Industry Revenue in EUR Million
Diagnostic Industry Revenue in EUR Million | © Medtech Europe IVD Market statistics: IVD market 2018

Molecular diagnostics (Dx) has emerged as one of the largest and fastest growing sectors of the IVD industry. Molecular Dx already enjoys more than 10 percent share of the entire German diagnostics market and boasts a growth rate more than twice that of the entire IVD market as such.

go to top

Log in

Please log in on this page with your log-in details.